- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: Simple Hypothesis.
Displaying page 1 of 3.
EudraCT Number: 2009-012752-24 | Sponsor Protocol Number: RG_09-016 | Start Date*: 2010-06-23 |
Sponsor Name:University of Birmingham [...] | ||
Full Title: High or Low Dose Syntocinon (Oxytocin) for delay in labour | ||
Medical condition: Approximately a third of women become delayed in their first labours and are given intravenous oxytocin in an attempt to increase their uterine contractions and thereby increase spontaneous vaginal... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006823-38 | Sponsor Protocol Number: DDOAT2006 | Start Date*: 2007-08-14 |
Sponsor Name:Rheinische Friedrichs-Wilhelms-Universität Bonn | ||
Full Title: D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis | ||
Medical condition: Female and male patients having suffered from venous thrombosis or pulmonary thromboembolism being treated with oral anticoagulant therapy (OAT) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005118-37 | Sponsor Protocol Number: H6L-MC-LFAN (e) | Start Date*: 2008-12-15 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo | |||||||||||||
Medical condition: Alzheimers Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Completed) FI (Completed) ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GR (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000108-27 | Sponsor Protocol Number: H8A-MC-LZBE | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease | |||||||||||||
Medical condition: Prodromal Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003425-96 | Sponsor Protocol Number: 11091 | Start Date*: 2011-12-15 |
Sponsor Name:University of Nottingham | ||
Full Title: Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial | ||
Medical condition: Helicobacter eradication to prevent ulcer bleeding in aspirin users | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007926-21 | Sponsor Protocol Number: H8A-MC-LZAN(b) | Start Date*: 2009-08-05 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Effect of Passive Immunization on the Progression of Alzheimer’s Disease: LY2062430 versus Placebo | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002204-84 | Sponsor Protocol Number: I6T-MC-AMAG | Start Date*: 2017-02-01 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY) | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) AT (Completed) NL (Completed) PL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002758-39 | Sponsor Protocol Number: H6L-MC-LFBC (c) | Start Date*: 2009-03-03 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Effect of LY450139, a γ-Secretase Inhibitor, on the Progression of Alzheimer’s Disease as Compared with Placebo | |||||||||||||
Medical condition: Alzheimers Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) HU (Completed) PT (Prematurely Ended) BG (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004623-36 | Sponsor Protocol Number: NCT01940692 | Start Date*: 2013-12-19 |
Sponsor Name:Ziekenhuis Oost-Limburg | ||
Full Title: Topical application of tranexamic acid compared to the intravenous administration in total hip arthroplasty with the direct anterior approach. A prospective, randomized, clinical trial. | ||
Medical condition: All adults (+ 18 yrs) who were scheduled for a primary unilateral total hip arthroplasty due to osteoarthritis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002381-23 | Sponsor Protocol Number: LOCAL/2012/PGC-01 | Start Date*: 2015-10-16 |
Sponsor Name:CHU de Nîmes | ||
Full Title: Comparison of the efficacy of IV paracetamol and IV ketoprofen in the treatment of renal colic in emergency department : a two-center double blind randomized study. | ||
Medical condition: Comparison of the efficacy of IV paracetamol and IV ketoprofen in the treatment of renal colic | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003941-42 | Sponsor Protocol Number: B4Z-SO-LY15 | Start Date*: 2005-02-11 |
Sponsor Name:Eli Lilly Sweden AB | ||
Full Title: A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ... | ||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that has its onset in childhood, and that is estimated to occur in 3% to 6% of school-age children. ADHD is characte... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001119-54 | Sponsor Protocol Number: H8A-MC-LZAX | Start Date*: 2013-09-27 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo | |||||||||||||
Medical condition: Mild Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) SE (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005625-39 | Sponsor Protocol Number: I8D-MC-AZET | Start Date*: 2016-09-16 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study) | |||||||||||||
Medical condition: Alzheimer’s Disease with Dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) NL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001811-26 | Sponsor Protocol Number: 202000261 | Start Date*: 2020-09-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring | ||
Medical condition: Crohn's disease, ulcerative colitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) BE (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020738-24 | Sponsor Protocol Number: Version 1.2 (20/06/2011) | Start Date*: 2010-10-12 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA) | |||||||||||||
Medical condition: Patients with established Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005270-10 | Sponsor Protocol Number: NALISO-II-20-1 | Start Date*: 2021-08-18 | |||||||||||
Sponsor Name:LABORATOIRES SMB S.A | |||||||||||||
Full Title: A randomized, partially blinded, parallel study to evaluate the effects of nacystelyn in combination with isotretinoin in the treatment of recalcitrant acne vulgaris. | |||||||||||||
Medical condition: Recalcitrant acne vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004783-22 | Sponsor Protocol Number: 67896049PAH4005 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:ACTELION Pharmaceuticals Ltd. | |||||||||||||
Full Title: A PRospective, Multicenter, Single-arm, Open label, Phase 4 Study of the Effects of Selexipag on RighT Ventricular RemOdeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic REsonan... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005352-17 | Sponsor Protocol Number: apaalz01 | Start Date*: 2012-08-29 | |||||||||||
Sponsor Name:University Bonn | |||||||||||||
Full Title: A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia | |||||||||||||
Medical condition: Apathy in Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002262-12 | Sponsor Protocol Number: DAPA-OB | Start Date*: 2021-05-17 |
Sponsor Name:Hospital Universitari Germans Trias i Pujol | ||
Full Title: "Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients with or without treatment with ACEIs". Pilot clinical trial of efficacy, low level of intervention, unicentric, ... | ||
Medical condition: This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glom... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003798-82 | Sponsor Protocol Number: R1578 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease; The STOP-ACEi Trial | |||||||||||||
Medical condition: Progressive, advanced (stage 4 or 5) chronic kidney disease (CKD). NB. There was not an appropriate therapeutic area in the drop down menu in E1-1. Have selected 'Male diseases of the urinary and... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.